Key Highlights
- N-Power Medicine raises total funding to $72M with Series B round led by Merck Global Health Innovation Fund.
- Expansion of oncology clinics and biopharmaceutical collaborations leveraging N-Power’s unique clinical trial integration platform.
- Innovative “human in the loop” model combines virtual and on-site staff with AI-enabled workflow automation.
- Over 7,000 patients enrolled in the Kaleido™ Registry for prospective, real-time, standardized patient data.
- Accelerated drug development timelines by enabling widespread oncologist and patient participation in clinical research.
Source: Business Wire
Notable Quotes
- “The average oncology drug takes 10 years to go from development to market, and eight of those years are typically spent in clinical trials. Today’s clinical trial paradigm is very inefficient at the centers that run trials and out of reach for the majority of oncologists and their patients in the community. Our vision is to radically accelerate drug development timelines through a new model where every oncologist and cancer patient can readily participate in advancing drug development. In the end we believe this is what patients will benefit from most.” — Mark Lee, M.D., Ph.D., Co-Founder and CEO at N-Power Medicine
- “At the Merck Global Health Innovation Fund we are focused on partnering with innovative companies such as N-Power that facilitate and optimize biopharmaceutical operations with the goal of improving patient care. N-Power’s unique approach offers the important opportunity to expand clinical research to more oncologists and their patients through standardized data collection, actionable insights, and the time and resources to participate in a model of accelerated drug development.” — David M. Rubin, Ph.D., Managing Director at Merck Global Health Innovation Fund
- “N-Power is working to solve major challenges for oncologists: managing electronic medical records, finding patients for clinical trials, and reporting requirements for CMS. Using N-Power’s ‘superscribes’ enables cancer doctors to focus more on patients, as the N-Power Staff manages the chart and consents the patient to join the registry. The registry allows us to find the trial candidates and send the required reports. The collaboration has been valuable.” — Barbara L. McAneny, MD, FASCO, MACP, CEO at New Mexico Cancer Center and Past President at the American Medical Association
SoHC's Take
N-Power Medicine’s innovative approach to integrating clinical trials into routine oncology care represents a significant advancement in the field of biopharmaceutical research. By addressing inefficiencies in the current clinical trial process and expanding access to more oncologists and their patients, N-Power Medicine is poised to accelerate drug development timelines substantially. This recent funding round, led by Merck Global Health Innovation Fund, underscores the industry’s confidence in N-Power’s vision and capabilities. The platform’s integration of AI and human expertise in clinical documentation and patient data management is a promising model that could set a new standard for clinical trials, ultimately benefiting patients by bringing life-saving therapies to market faster.
